Table 3 Multivariable survival analysis for genotype biomarkers. *G allele. 95%CI 95% confidence interval, HR hazard ratio, RD residual disease, PFS progression-free survival, OS overall survival. In the multivariable analysis, a P-value cut-off of ≤ 0.05 was considered statistically significant. Predictive model, a model exploring if the association between a biomarker and survival are significantly different depending on treatment arms: HR, 95%CI and P-values come from the interaction term. Clinical factors prognostic for PFS/OS were included in the model
Covariate name | Predictive model | |||||
|---|---|---|---|---|---|---|
PFS | OS | |||||
HR | 95%CI | P-value | HR | 95%CI | P-value | |
Clinical biomarker | ||||||
 FIGO stage (III/IV vs. I/II) | 3.171 | 2.118–4.747 | < 0.001 | 2.434 | 1.409–4.205 | 0.001 |
 Debulking surgery outcome (≤ 1 cm vs. > 1 cm RD) | 0.506 | 0.394–0.651 | < 0.001 | 0.396 | 0.274–0.573 | < 0.001 |
Genotype biomarker | ||||||
 rs2305945 (VEGFR-2)* | 0.794 | 0.961–1.650 | 0.095 | – | – | ns |
 Bevacizumab | 0.497 | 0.296–0.833 | 0.008 | – | – | ns |
Predictive significance | ||||||
 rs2305945 (VEGFR-2) in the bevacizumab arm* (interaction) | 1.592 | 1.110–2.284 | 0.012 | – | – | ns |